The Drug Enforcement Administration (DEA) has scheduled a hearing from November 12 to November 22, 2024, to consider classifying the psychedelic compounds DOI and DOC as Schedule I drugs, which could hinder ongoing medical research. Concurrently, the DEA also announced a hearing for December 2, 2024, to discuss rescheduling marijuana from Schedule I to Schedule III, delaying the decision until after the 2024 presidential election. This delay has caused a significant drop in cannabis stock prices, with companies like Canopy Growth and Tilray Brands experiencing notable declines. Stakeholders argue that rescheduling marijuana could bridge the gap between state and federal laws, but the extended wait maintains regulatory uncertainty for businesses. Opinions on the rescheduling's impact vary, with more confidence in Kamala Harris supporting the change compared to Donald Trump. These hearings reflect ongoing debates over drug policy and its implications for medical research and the cannabis industry.